Comparative Pharmacology
Head-to-head clinical analysis: LUCEMYRA versus NEXICLON XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUCEMYRA versus NEXICLON XR.
LUCEMYRA vs NEXICLON XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LUCEMYRA (lofexidine) is a central alpha-2 adrenergic agonist that reduces the release of norepinephrine in the brain, thereby alleviating opioid withdrawal symptoms.
NEXICLON XR is a centrally acting alpha-2 adrenergic agonist that stimulates alpha-2 adrenergic receptors in the brainstem, reducing sympathetic outflow from the central nervous system, resulting in decreased peripheral vascular resistance and reduced blood pressure. The extended-release formulation provides sustained drug release.
18 mg orally 5-6 times daily (maximum 108 mg/day) for 7-14 days then tapered over 4-6 weeks.
NEXICLON XR (clonidine extended-release) is administered orally. Typical adult dose for hypertension: 0.1 mg to 0.2 mg once daily at bedtime. May be titrated up to 0.6 mg/day. For ADHD: initial 0.1 mg once daily, adjusted weekly by 0.1 mg/day; maximum 0.4 mg/day.
None Documented
None Documented
Terminal half-life approximately 5-6 hours; no clinically significant accumulation with twice-daily dosing.
Terminal elimination half-life: 12–15 hours; clinical context: once-daily dosing maintains therapeutic levels.
Renal: 63% as unchanged drug; fecal: 27% (mostly unchanged); biliary: minimal (<5%).
Renal: 70% as unchanged drug; biliary/fecal: 30% as metabolites.
Category C
Category C
Alpha-2 Adrenergic Agonist
Alpha-2 Adrenergic Agonist